Medical Science News

RSS

Increase in levels of P450 protein creates EET molecules that lower blood pressure

If you are one of the millions of Americans with high blood pressure, more help is on the way. That's because a new research study published in the October 2010 print issue of The FASEB Journal shows that a protein, called P450, metabolizes arachidonic acid in our blood vessel walls to create a tiny molecule with a big name-epoxyeicosatrienoic acid (EET)-which in mice, turns off genes responsible for vascular inflammation and ultimately relaxes blood vessels to lower blood pressure. This protein and genes are also present in humans.

1 Oct 2010

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

A new report published in the October 2010 print issue of The FASEB Journal offers a ray of hope in the search for new cancer drugs. By examining the seemingly conflicting roles of how oncogenes and tumor suppressor genes handle cellular stress, scientists from the Institute for Advanced Studies in New Jersey argue that each of these opposing systems could be potent drug targets in the effort to stop cancer. In addition, their hypothesis provides new insights into what contributes to immunological disorders such as chronic inflammation and autoimmune diseases.

1 Oct 2010

Lying creates desire to clean the 'dirty' body part: Study

Apparently your mom had it right when she threatened to wash your mouth out with soap if you talked dirty. Lying really does create a desire to clean the "dirty" body part, according to a University of Michigan study.

1 Oct 2010

Report finds development of multiple myeloma is tied to 'hypomethylation'

DNA methylation - a modification of DNA linked to gene regulation - is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).

1 Oct 2010

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

The potential for stem cells derived from menstrual blood to benefit stroke sufferers will be jointly investigated by researchers at the University of South Florida, Cryo-Cell International, Inc., a global stem cell company based in Oldsmar, FL, and Saneron CCEL Therapeutics, Inc. a Tampa-based biotechnology company.

1 Oct 2010

Researchers study gene interactions for personalized drug prescriptions

The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.

1 Oct 2010

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

The National Institute of General Medical Sciences (NIGMS) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $30 million grant to study the structure and function of thousands of biomedically important proteins.

1 Oct 2010

Personalized cancer drug delivery could soon be a reality

Imagine the day a machine can draw your blood, screen it for genetic mutations and chemical variations that can cause cancer, and pop out a drug tailor-made for your DNA.

1 Oct 2010

Researchers discover new factors that regulate fat formation

By creating a "map" of histone modifications in fat cells, investigators have discovered two new factors that regulate fat formation, a key step on the road to better understanding obesity, diabetes and other metabolic disorders.

1 Oct 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Healthy and Essential develops World's first limited edition fish oil SuperFood

Blackpool Football Club surprised many last season and they continue to defy the so called experts with some excellent performances so far in their debut Premier League season. In tribute of Blackpool's amazing achievements, a Lancashire based Company called Healthy and Essential Ltd has developed the World's first limited edition fish oil SuperFood called 'Tangerine Dream'.

30 Sep 2010

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Agilent Technologies Inc. today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.

30 Sep 2010

ICM, University of Warsaw partner with AAAS to provide site-wide access to Science publication

Washington, D.C. and Warsaw, Poland: The Interdisciplinary Centre for Mathematical and Computational Modelling (ICM), University of Warsaw, has partnered with the American Association for the Advancement of Science (AAAS) in a national site licensing agreement to provide 922 research and scientific institutions throughout Poland with site-wide access to Science , the flagship publication of AAAS.

30 Sep 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

Study suggests H2O2 can act as anti-inflammatory compound

A major blow to the free radical theory of aging, which had lead the research in aging for more than 50 years and fuels a multimillionaire anti-aging industry has just been published by Portuguese scientists from the University of Minho. According to the theory, free radicals provoke oxidative damage and this is the cause of aging.

30 Sep 2010

New caproKits enable investigation of small molecule–protein interactions

caprotec bioanalytics GmbH announced today the commercial launch of three new caproKits, enabling the discovery, identification and characterization of proteins for applications in functional proteomics and drug development.

30 Sep 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Long-term high protein diet has negative effects on body mass, hormones and genes

A high protein diet during development primes the body to react unhealthily to future food binges. A study on juvenile rats, published in BioMed Central's open access journal Nutrition and Metabolism, suggests that lasting changes result from altering the composition of the first solid food that is consumed throughout growth into early adulthood.

30 Sep 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

There is growing evidence that two neurotransmitters dopamine and glutamate are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem solving.

30 Sep 2010

Medical Science News

Increase in levels of P450 protein creates EET molecules that lower blood pressure

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

Lying creates desire to clean the 'dirty' body part: Study

Report finds development of multiple myeloma is tied to 'hypomethylation'

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

Researchers study gene interactions for personalized drug prescriptions

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

Personalized cancer drug delivery could soon be a reality

Researchers discover new factors that regulate fat formation

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Healthy and Essential develops World's first limited edition fish oil SuperFood

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

ICM, University of Warsaw partner with AAAS to provide site-wide access to Science publication

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

Study suggests H2O2 can act as anti-inflammatory compound

New caproKits enable investigation of small molecule–protein interactions

Cardium expands wound healing and tissue regeneration portfolio

Long-term high protein diet has negative effects on body mass, hormones and genes

Penn Medicine selected as study site for PPMI

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News